Immune system activation via presentation of multiple tumor-associated antigens

The concept "Immune system activation via presentation of multiple tumor-associated antigens" refers to an immunological process rather than a specific molecule or receptor. It describes the mechanism whereby the immune system—primarily T cells—identifies and responds to cancer cells through the recognition of tumor-associated antigens (TAAs) presented on the surface of tumor cells via major histocompatibility complex (MHC) molecules[1][2][3][4][5]. These antigens can be specific to tumor cells (TSAs/neoantigens) or overexpressed self-antigens found mainly on tumors (TAAs)[5]. Therapies built upon this mechanism include tumor vaccines and immune checkpoint inhibitors, which seek to boost the immune response against cancer by enhancing antigen presentation and overcoming immune suppression[1][2][4][5]. The field is challenged by tumor immune evasion strategies such as antigen downregulation, induction of immune tolerance, and creation of an immunosuppressive microenvironment[3][4][5]. This entry is not a canonical therapeutic target but a biological process or therapeutic strategy involving many molecular components, especially antigens, antigen-presenting molecules (e.g., MHC), and immune cell receptors. Thus, it should not be catalogued as a molecule or receptor target.

Other names

Tumor antigen presentationTumor antigen immune activationAntigen presentation in cancer immunotherapy

Induction of T cell response via MHC-mediated presentation of tumor-associated antigens; Activation of cytotoxic T lymphocytes specific to tumor antigens; Immune checkpoint inhibition to enhance tumor antigen recognition and response